Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results And Clinical Program Updates
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN),
a clinical-stage oncology company focused on developing next-generation
radiopharmaceuticals as precision medicines, today announced financial results
for the second quarter ended June 30, 2022 and provided an update on clinical
and corporate developments.
To
read more please visit:
Fusion
Pharmaceuticals Announces Second Quarter 2022 Financial Results And Clinical
Program Updates
Source: Fusion